Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 ...
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data 55% of BriaCell patients[1] ...
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune ...
Philadelphia & Vancouver, British Columbia – October 1, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...
Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with ...
FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in ...
Philadelphia & Vancouver, British Columbia – September 12, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...
Philadelphia & Vancouver, British Columbia – September 11, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...
• Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in ...
• BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with ...
Accessibility Tools